The anticipated size of the Canine Dilated Cardiomyopathy Drugs Market in 2022 was USD 3480 million and is estimated to be USD 3643.6 million in 2023. Canine dilated cardiomyopathy drugs are mainly used in the treatment of heart muscle-related ailments.
According to Future Market Insights, the canine dilated cardiomyopathy drugs market is predicted to expand at a CAGR of 4.80% between 2023 and 2033, totaling around USD 5822.9 million by 2033.
The global canine dilated cardiomyopathy drugs market demand is anticipated to be valued at USD 3480 million in 2022 and is forecasted to expand at a CAGR of 4.93%.
It is estimated to be valued at USD 5500 million from 2022 to 2032. Growth of the canine dilated cardiomyopathy market is attributed to its global utilization across the healthcare industry.
Canine dilated cardiomyopathy drugs are used to treat heart muscle diseases, which cause the heart to weaken and enlarge. Further, canine dilated cardiomyopathy is prevalent in certain breeds of dogs and is observed to be rare in crossbreed dogs.
Canine dilated cardiomyopathy drugs are directed at enhancing the systolic (pump) function of the heart, dilating the peripheral blood vessels to lower ventricular workload, and controlling heart rate and cardiac arrhythmias.
Moreover, canine dilated cardiomyopathy drug treatment goals are achieved by the administration of cardiac medication which may be delivered through injections in an emergency situation or orally in stable animals.
Asia Pacific is considered to be a dominant region for the canine dilated cardiomyopathy market during the forecast period, owing to the increasing pet culture in the region.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | USD 3480 million |
| Projected Forecast Value (2023) | USD 3643.6 million |
| Projected Forecast Value (2033) | USD 5822.9 million |
| Growth rate | 4.80% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global canine dilated cardiomyopathy drugs market expanded at a CAGR of 3.7% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 4.80% between 2023 and 2033.
Key factor that is expected to propel the growth of the canine dilated cardiomyopathy market during the forecast period includes rising health benefits for pet animals. However, factor that is expected to hinder the growth of the canine dilated cardiomyopathy market during the forecast period includes the high cost and side effects associated with products and treatments
Potential Growth of the Pet Industry
A significant factor that is expected to accelerate the growth of the canine dilated cardiomyopathy market during the forecast period includes the potential growth of the pet industry.
Dogs are estimated to account for a leading share of the pet industry due to rising health benefits for pet animals, which in turn is expected to fuel the growth of the canine dilated cardiomyopathy market during the forecast period.
Rise in the Prevalence of Cardiac Diseases with Technological Advancements
Increasing prevalence of cardiac diseases, technological advancement in diagnostic treatments, and life expectancy of animals are some other factors that are expected to propel the growth of the canine dilated cardiomyopathy drugs market during the forecast period.
Principal Consultant
High Costs and Side Effects Associated with Products and Treatments
Key factor that is expected to hamper the growth of the canine dilated cardiomyopathy market during the forecast period includes the high cost and side effects associated with products and treatments.
Moreover, the lack of veterinary infrastructure and poor transportation links in some regions are a few other factors expected to hinder the market growth.
The High Prevalence of Disease Conditions like Cancer and Cardiovascular Diseases
Asia Pacific is the dominant market for canine dilated cardiomyopathy, owing to the high prevalence of disease conditions such as cancer and cardiovascular diseases in the region where India expands at a CAGR of 6.10% and China expands at a CAGR of 5.30%.
These both markets are considered to be promising markets for the growth of dilated cardiomyopathy market due to increasing incidences of cancer among patients.
Increase in various therapy devices including implantable cardioverter-defibrillators (ICDs), biventricular pacemakers, and heart pump in the Asia Pacific region like Japan is expected to fuel the growth of the canine dilated cardiomyopathy market in the region with a value share of 4.9% and Australia is said to expand at a CAGR of 4.20%.
Asia Pacific’s canine dilated cardiomyopathy market is anticipted to expand at a 3% CAGR during the forecast period.
Boost in Pet Culture
North America is anticipated to witness growth at a significnt rate over the forecast period with a market share of 33.1%, owing to the increasing pet culture in the region. This factor is expected to fuel the growth of the canine dilated cardiomyopathy market in the region.
Growing incidences of cancer in the United States of America are expected to accelerate the market growth in the region in the forthcoming years with a market share of 34.1%.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Injectable is Used in this Market
Injectable holds a significant market share of 54.7% because of the instant relief they are provided with in times of discomfort and the medicine starts reacting at a fast rate.
Institutional Sales are Preferred Most in this Market
Institutional sales mainly include veterinary hospitals or clinics holding a value share of 62.1% as pets or even street animals suffering from such a disease are likely to get cured in veterinaries provided with proper treatment facilities.
Angiotensin-converting Enzyme (ACE) Inhibitors hold the most Dominant Position in the Market
Angiotensin-converting Enzyme (ACE) Inhibitors hold a market value of 55.6% which is a class of medication mainly used in the treatment of high blood pressure in dogs as they work by restraining the enzyme angiotensin-converting enzyme (ACE). Further, they control blood pressure and the movement of fluids through the body.
Some of the prominent players profiled in the global market
Important Developments of the Key Players in the Market
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.80% from 2023 to 2033 |
| Market value in 2023 | USD 3643.6 million |
| Market value in 2033 | USD 5822.9 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | By Country, By Drug, By Route of Administration, By Distribution Channel |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East & Africa |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Rest of Latin America, Germany, The United Kingdom, France, Spain, Italy, Rest of Western Europe, Poland, Russia, Czech Republic, Romania, Rest of Eastern Europe, India, Bangladesh, Australia, New Zealand, Rest of South Asia and Pacific, China, Japan, South Korea, GCC Countries, South Africa, Israel, Rest of Middle East and Africa |
| Key Companies Profiled | C.H. Boehringer Sohn AG & Co.; KG, Merck & Co.; Dechra Pharmaceuticals PLC, Zoetis Inc.; Bayer AG; Orion, Elanco; SAVA Vet; Elanco; Zoetis Inc.; Boehringer Ingelheim; Merck |
| Customisation Scope | Available on Request |
The potential growth of the pet industry is driving the market.
From 2018 to 2022, the market registered a CAGR of 3.7%.
The growth potential of the market is 4.80% CAGR through 2033.
The industry is expected to be worth USD 5822.9 million in 2033.
North America is anticipated to experience a market share is 33.1%.
1. Executive Summary
2. Market Overview
3. Market Background
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. ACE Inhibitors
5.2. Vasodilators
5.3. Diuretics
5.4. Angiotensin II Receptor Blockers (ARB)
5.5. Cardiac Glycosides
5.6. Anti-arrhythmic
5.7. Pimobenden
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Oral
6.2. Injectable
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Institutional Sales
7.1.1. Veterinary Hospitals
7.1.2. Veterinary Clinics
7.2. Retail Sales
7.2.1. Retail Pharmacies
7.2.2. Drug Stores
7.2.3. Online Pharmacies
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. North America
8.2. Latin America
8.3. Western Europe
8.4. Eastern Europe
8.5. South Asia and Pacific
8.6. East Asia
8.7. Middle East and Africa
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16. Key Countries Market Analysis
17. Market Structure Analysis
18. Competition Analysis
18.1. C.H. Boehringer Sohn AG & Co.
18.2. KG, Merck & Co.
18.3. Dechra Pharmaceuticals PLC, Zoetis Inc.
18.4. Bayer AG
18.5. Orion, Elanco
18.6. SAVA Vet
18.7. Elanco
18.8. Zoetis Inc.
18.9. Boehringer Ingelheim
18.10. Merck
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Canine Dilated Cardiomyopathy Drugs Market
